Introduction
Materials and methods
Results
Patient demographics and clinical data (patients N = 50; renal units N = 55) | n (%) ± SD |
---|---|
Male:female (n) | 35:15 |
Mean age, years (range) | 58 (2–88) |
Stone size (cumulative) in mm | 21 (range 15–52 mm) |
Stone location
| |
Lower calyx | 34 |
Renal pelvis | 15 |
Upper calyx | 11 |
Middle calyx | 5 |
Pelvi-ureteric junction | 4 |
Ureter | 15 |
(Multiple bilateral kidney stones) | (36) |
(Multiple kidney + ureter) | (19) |
Number of renal units (55) | |
Access sheath (%) | (62%) |
Size | |
9.5/11.5 | 6 |
12/14 | 26 |
14/16 | 2 |
Pre-operative stent, n (%) | 25 (45%) |
Post-operative stent placement, n (%) | 51 (93%) |
Mean hospital stay (range) | 0.6 days (0–7) |
Complications | 1 (Clavien IV) (Urosepsis, ICU admission) |
Stone-free rate, n (%) | Initial 93% Final 98% (1.1 ± 0.27 procedure per patient) |
Stone composition
| |
Calcium oxalate monohydrate | 11 |
Calcium phosphate carbonate | 2 |
Calcium oxalate dihydrate + calcium oxalate monohydrate | 4 |
Magnesium ammonium phosphate hexahydrate + calcium phosphate carbonate | 7 |
Calcium oxalate monohydrate + calcium phosphate carbonate | 7 |
Calcium oxalate dihydrate + calcium oxalate monohydrate + calcium phosphate carbonate | 5 |
Calcium hydrogen phosphate dihydrate | 1 |
Magnesium ammonium phosphate | 3 |
Cystine | 3 |
Uric acid | 7 |